Viral infection of the heart: pathogenesis and diagnosis

• Autorzy: Kuffner M. , Pawlak A. , Przybylski M.
• Języki publikacji: EN

Abstrakty

EN

Viral infections of the heart cause serious clinical problems, either as infectious myocarditis, which usually is a consequence of acute infection or as idiopathic dilated cardiomyopathy, resulting rather from a chronic infection. This minireview presents an up-to-date view on pathomechanisms of viral infection of the heart tissues, the role of immune system in controlling infectious process at its various stages and current possibilities of recognizing viral infection of the heart with use of both cardiological and virological methods. Our goal was to present the variety of known viral agents causing heart infection, level of complexity in mutual virus-cell interactions, and consequent clinical scenarios.

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2016
• Tom: 65
• Numer: 4
• Opis fizyczny: p.391-398,fig.,ref.

Twórcy

autor

Kuffner M.

• Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland
• Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

autor

Pawlak A.

• Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland
• Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

autor

Przybylski M.

• Chair and Department of Medical Microbiology, Medical University of Warsaw, Warsaw, Poland

Bibliografia

• Abston E.D., M.J. Coronado, A. Bucek, D. Bedja, J. Shin, J.B. Kim, E. Kim, K.L. Gabrielson, D. Georgakopoulos, W. Mitzner and others. 2012. Th2 regulation of viral myocarditis in mice: different roles for TLR3 vs. TRIF in progression to chronic disease. Clin. Dev. Immunol. 2012: 129486.
• Aretz H.T. 1987. Myocarditis: the Dallas criteria. Hum. Pathol. 18: 619–624.
• Blauwet L.A. and L.T. Cooper. 2010. Myocarditis. Prog. Cardiovasc. Dis. 52(4): 274–88.
• Basso C., F. Calabrese, A. Angelini, E. Carturan and G. Thiene. 2013. Classification and histological, immunohistochemical, and molecular diagnosis of inflammatory myocardial disease. Heart Fail. Rev. 18(6): 673–681.
• Baughman K.L. 2006. Diagnosis of myocarditis: death of Dallas criteria. Circullation. 113: 593–595.
• Bergelson J.M., J.A. Cunningham, G. Droguett, E.A. Kurt-Jones, A. Krithivas, J.S. Hong, M.S. Horwitz, R.L. Crowell and R.W. Finberg. 1997. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320–1323.
• Bock C.T., K. Klingel and R. Kandolf. 2010. Human parvovirus B19-associated myocarditis. N. Engl. J. Med. 362(13): 1248–1249.
• Bowles N.E., J. Ni, D.L. Kearney, M. Pauschinger, H.P. Schultheiss,R. McCarthy, J. Hare, J.T. Bricker, K.R. Bowles and J.A. Towbin.2003. Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. J. Am. Coll. Cardiol. 42(3): 466–472.
• Bültmann B.D., K. Klingel, K. Sotlar, C.T. Bock, H.A. Baba,M. Sauter and R. Kandolf. 2003. Fatal parvovirus B19-asso-ciated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. Hum. Pathol. 34: 92–95.
• Caforio A.L., F. Calabrese, A. Angelini, F. Tona, A. Vinci,S. Bottaro, A. Ramondo, E. Carturan, S. Iliceto, G. Thiene and others. 2007. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur. Heart J. 28(11): 1326–1333.
• Cooper L.T., K.L. Baughman, A.M. Feldman, A. Frustaci,M. Jessup, U. Kühl, G.N. Levine, J. Narula, R.C. Starling, J. Towbinand others. 2007. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardio-logy, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J. Am. Coll. Cardiol. 50(19): 1914–1931.
• Dennert R., H.J. Crijns and S. Heymans. 2008. Acute viral myocarditis. Eur. Heart. J. 29(17): 2073–2082.
• Fairweather D., S. Frisancho-Kiss, S.A. Yusung, M.A. Barrett,S.E. Davis, S.J. Gatewood, D.B. Njoku and N.R. Rose. 2004. IFN-g protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines TGF-b1, IL-1b, and IL-4 in the heart. Am. J. Pathol. 165: 1883–1894.
• Fairweather D. and N. Rose. 2007. Coxsackievirus-induced myocarditis in mice: A model of autoimmune disease for studying immunotoxicity. Methods. 41: 118–122.
• Fuse K., G. Chan, Y. Liu, P. Gudgeon, M. Husain, M. Chen, W.C. Yeh, S. Akira and P.P. Liu. 2005. Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation. 112: 2276–2285.
• Herzum M., V. Ruppert, B. Kuytz, H. Jomaa, I. Nakamura and B. Maisch. 1994. Coxsackievirus B3 infection leads to cell death of cardiac myocytes. J. Mol. Cell Cardiol. 26(7): 907–913.
• Huber S.A., D. Sartini and M. Exley. 2002. Vgamma4(+) T cells promote autoimmune CD8(+) cytolytic T-lymphocyte activation in coxsackievirus B3-induced myocarditis in mice: role for CD4(+) Th1 cells. J. Virol. 76: 10785–10790.
• Kawai C. 1999. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation. 99: 1091–100.
• Kawai C. and A. Matsumori. 2013. Dilated cardiomyopathy update: infectious-immune theory revisited. Heart Fail. Rev. 18(6): 703–714.
• Kühl U., M. Pauschinger, B. Seeberg, D. Lassner, M. Noutsias,W. Poller and H.P. Schultheiss. 2005. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 112(13): 1965–1970.
• Kühl U., M. Pauschinger, P.L. Schwimmbeck, B. Seeberg, C. Lober,M. Noutsias, W. Poller and H.P. Schultheiss. 2003. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 107: 2793–2798.
• Kühl U. and H.P. Schultheiss. 2009. Viral myocarditis: diagnosis, aetiology and management. Drugs. 69(10): 1287–1302.
• Lafyatis R. and A. Farina. 2012. New insights into the mechanisms of innate immune receptor signalling in fibrosis. The Open Rheum. J. 6(Suppl 1: M2): 72–79.
• Leslie K., R. Blay, C. Haisch, A. Lodge, A. Weller and S. Huber. 1989. Clinical and experimental aspects of viral myocarditis. Clin. Microbiol. Rev. 2(2): 191–203.
• Li K., W. Xu, Q. Guo, Z. Jiang, P. Wang, Y. Yue and S. Xiong. 2009. Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility toviral myocarditis. Circ. Res. 105: 353–364.
• Luo H., J. Zhang, C. Cheung, A. Suarez, B.M. McManus andD. Yang. 2003. Proteasome inhibition reduces coxsackievirus B3 replication in murine cardiomyocytes. Am. J. Pathol. 163: 381–385.
• Mahfoud F, B. Gärtner, M. Kindermann, C. Ukena, K. Gadomski, K. Klingel, R. Kandolf, M. Böhm and I. Kindermann. 2011. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J. 32: 897–903.
• Mahrholdt H., C. Goedecke, A. Wagner, G. Meinhardt, A. Athanasiadis, H. Vogelsberg, P. Fritz, K. Klingel, R. Kandolf andU. Sechtem. 2004. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 109: 1250–1258.
• Maisch B. and S. Pankuweit. 2013. Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives. Heart Fail. Rev. 18(6): 761–795.
• Maisch B., B.D. Bültmann, S. Factor, H.J. Gröne, G. Hufnagel, K. Kawamura, U. Kühl, E.J. Olsen, S. Pankuweit and R. Virmani. 1999. World Heart Federation con-sensus conferences’ definition of inflammatory cardiomyopathy (myocarditis): report from two expert committees on histology and viral cardiomyopathy. Heartbeat. 4: 3–4.
• Martin A.B., S. Webber, F.J. Fricker, R. Jaffe, G. Demmler,D. Kearney, Y.H. Zhang, J. Bodurtha, B. Gelb and J. Ni. 1994. Acute myocarditis. Rapid diagnosis by PCR in children. Circulation. 90: 330–339.
• Martino T.A., P. Liu and M.J. Sole. 1994. Viral infection and the pathogenesis of dilated cardiomyopathy. Circ. Res. 74: 182–188.
• Mason J.W., J.B. O’Cornell, A. Herscowitz, N.R. Rose, B.M. McMa-nus, M.E. Bilingham and T.E. Moon. 1995. A Clinical trial of immunosupressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N. Engl. J. Med. 333: 269–275.
• Negishi H., T. Osawa, K. Ogami, X. Ouyang, S. Sakaguchi,R. Koshiba, H. Yanai, Y. Seko, H. Shitara, K. Bishop and others. 2008. A critical link between Toll-like receptor 3 and type I interferon signaling pathways in antiviral innate immunity. Proc. Natl. Acad. Sci. USA 105(51): 20446–20451.
• Nie X., G. Zhang, D. Xu, X. Sun, Z. Li, X. Li, X. Zhang, F. He and Y. Li. 2010. The VP1-unique region of parvovirus B19 induces myocardial injury in mice. Scand. J. Infect. Dis. 42: 121–128.
• O’Malley A., C. Barry-Kinsella, C. Hughes, P. Kelehan, D. Devaney, E. Mooney and J. Gillan. 2003. Parvovirus infects cardiac myocytes in hydrops fetalis. Pediatr. Dev. Pathol. 6: 414–420.
• Pankuweit S., R. Moll, U. Baandrup, I. Portig, G. Hufnagel andB. Maisch. 2003. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum. Pathol. 34: 497–503.
• Pankuweit S. and K. Klingel. 2013. Viral myocarditis: from experimental models to molecular diagnosis in patients. Heart Fail. Rev. 18(6): 683–702.
• Sagar S., P.P. Liu and L.T. Jr. Cooper. 2012. Myocarditis. Lancet 379(9817): 738–747
• Shi Y., C. Chen, U. Lisewski, U. Wrackmeyer, M. Radke, D. Westermann, M. Sauter, C. Tschöpe, W. Poller, K. Klingel and others. 2009. Cardiac deletion of the Coxsackievirus-adenovirus receptor abolishes Coxsackievirus B3 infection and prevents myocarditis in vivo. J. Am. Coll. Cardiol. 53: 1219–1226.
• Schmidt-Lucke C., F. Spillmann, T. Bock, U. Kühl, S. Van Linthout, H.P. Schultheiss and C. Tschöpe. 2010. Interferon Beta Modulates Endothelial Damage in Patients with Cardiac Persistence of Human Parvovirus B19 Infection. J. Infect. Dis. 201–206
• Stewart P.L. and G.L. Nemerow. 2007. Cell integrins: commonly used receptors for diverse viral pathogens. Trends in Microbiology 15(11): 500–507.
• Tanaka T., T. Kanda, B.M. McManus, H. Kanai, H. Akiyama, K. Sekiguchi, T. Yokoyama and M. Kurabayashi. 2001. Overexpres-sion of interleukin-6 aggravates viral myocarditis: impaired increase in tumor necrosis factor-α. J. Mol. Cell. Cardiol. 33: 1627–1635.
• Tzang B.S., T.M. Lin, C.C. Tsai, J.D. Hsu, L.C. Yang and T.C. Hsu. 2011. Increased cardiac injury in NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein. Mol. Immunol. 48: 1518–1524.
• Woodruff J.F. 1980. Viral myocarditis. A review. Am. J. Pathol. 101(2): 425–484.
• Yajima T. 2011. Viral myocarditis: potential defense mechanisms within the cardiomyocyte against virus infection. Future Microbiol. 6: 551–566.
• Yasukawa H., T. Yajima, H. Duplain, M. Iwatate, M. Kido,M. Hoshijima, M.D. Weitzman, T. Nakamura, S. Woodard,D. Xiong and others. 2003. The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. J. Clin. Invest. 111(4): 469–478.
• Yuan J., A.L. Cao, M. Yu, Q.W. Lin, X. Yu, J.H. Zhang, M. Wang, H.P. Guo and Y.H. Liao. 2010. Th17 cells facilitate the humoral immune response in patients with acute viral myocarditis. J. Clin. Immunol. 30: 226–234.

Identyfikatory

DOI

10.5604/17331331.1227664